Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
Use of Cost-effectiveness Evidence in US Health Care: Seminar Briefing
1 April 2014
Just published by OHE, this Seminar Briefing summarises remarks at an OHE Lunchtime Seminar by Dr James Chambers of the Center for the Evaluation of Value…
Benefiting from the Promise of Personalised Medicine: Recent OHE Presentations
18 February 2014
Focusing on England, these two presentations describe the core economic considerations in making the most of targeted therapy. OHE’s Adrian Towse participated in a two-day workshop…
OHE at HESG: Value-based Assessment in the UK; Developing the EQ-5D-5L
23 January 2014
OHE’s contributions focused on approaches to implementing UK value-based assessment and the details of creating an EQ-5D-5L value set for England. The Health Economists’ Study Group…
Opportunity Costs of Implementing NICE Decisions in NHS Wales
1 June 2014
This new research from the OHE examines how Local Health Boards (LHBs) in Wales adjust spending to meet the statutory requirement of providing access to technologies…
The Expanding Value Footprint of Oncology Treatments
1 May 2014
This report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. Included are the ten cancer drugs approved by the EMA during 2003–2005. Decisions by France’s HAS, NICE and Aetna in the US are analysed.
What is the Role of HTA for Biosimilars?
1 April 2014
This Briefing summarises the results of a roundtable convened by OHE to discuss using HTA to assess biosimilars – including which methods are most appropriate in…
Can the US Afford to Ignore Cost-effectiveness Evidence?
1 March 2014
Cost-effectiveness analysis plays a limited role in US health care compared to many other countries. In this Seminar Briefing, Dr James Chambers, Center for the Evaluation…
Inconsistent Use of Cost-effectiveness Thresholds in NHS Scotland
12 December 2013
This study finds an apparent mismatch in the decision making approaches of the SMC and the NHS Boards. OHE today released a Research Paper on the…
Using MCDA to Assess the Value of Treatments for Rare Diseases
5 December 2013
A pilot study demonstrated the value of involving a range of stakeholders in MCDA for rare disease therapies. According to a study just published by the…